Estrogen screening in evaluation of fetal outcome and infant’s development
- 1 January 1986
- journal article
- research article
- Published by Walter de Gruyter GmbH in jpme
- Vol. 14 (5) , 279-291
- https://doi.org/10.1515/jpme.1986.14.5.279
Abstract
In an unselected obstetric population of 869 women serial determinations of estriol in serum and urine were performed from the 28th week of pregnancy until delivery. Clinical management was based on ultrasound and nonstress/contraction stress tests only. Data on the development of the infants were available after 1 year in 759 cases (89%) and after 2 years in 661 cases (78%). Serum free estriol (E3) screening during weeks 28-34 of pregnancy revealed a significantly increased risk for reduced Apgar scores, growth retardation and postnatal complications in pregnancies with decreased levels (p < 0.001). The development of the children was disturbed by a higher incidence of childhood diseases, retardation in speech and bowel and bladder control. The urinary estrogen determinations (UE) during this period of pregnancy showed only a vague connection with birth weight and Apgar scores (p < 0.05) and no connection to the infant''s development. Serial determinations of E3 after the 35th week of pregnancy increased the significance for all parameters tested. If the estrogen concentration was determined in the last 2 weeks before delivery, 50% of the SGA and 60% of the endangered cases could be diagnosed. After reduced E3 serial levels neurological sequelae, reduced body weight, retarded speech and late development of bowel and bladder control were significantly more frequent at age two than after normal E3 levels. The differences obtained by serial UE determinations were less evident. Considering cost-benefit-calculations, an E3 screening of every pregnant woman cannot recommended. In pregnancies at risk serial E3 determinations allow better prognostication of fetal well-being. In the case of reduced E3 values maximum postpartum care should be made available for all newborns. Special support should be given to the early infant''s development after reduced E3 values have been observed.This publication has 27 references indexed in Scilit:
- PLASMA OESTRIOL AND PLACENTAL PROTEINS: A CROSS-SECTIONAL STUDY AT 38 WEEKS GESTATIONBJOG: An International Journal of Obstetrics and Gynaecology, 2008
- Impact of routine fetal monitoring during labor on fetal outcome with long-term follow-upAmerican Journal of Obstetrics and Gynecology, 1981
- Value of Total Serum Oestriol and Human Placental Lactogen in the Assessment of Fetal‐Placental FunctionAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1979
- hCS, estriol and oxytocinase in maternal serum and neonatal condition in high risk pregnanciesjpme, 1979
- Plasma unconjugated estriol values in high-risk pregnancyAmerican Journal of Obstetrics and Gynecology, 1977
- An analysis of the utility of plasma immunoreactive estrogen measurements in determining delivery time of gravidas with a fetus considered at high riskAmerican Journal of Obstetrics and Gynecology, 1976
- PLASMA OESTRIOL AND HUMAN PLACENTAL LACTOGEN MEASUREMENTS IN PATIENTS WITH HIGH RISK PREGNANCIESBJOG: An International Journal of Obstetrics and Gynaecology, 1976
- Comparison Between Plasma and Urinary Oestrogen Measurements in Predicting Fetal RiskAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1974
- CURRENT STATUS OF ESTROGEN ASSAYS IN OBSTETRICS AND GYNECOLOGYObstetrical & Gynecological Survey, 1972
- Correlation of estriol excretion patterns of pregnant women with subsequent development of their childrenAmerican Journal of Obstetrics and Gynecology, 1969